<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01720069</url>
  </required_header>
  <id_info>
    <org_study_id>VR506/2/004</org_study_id>
    <nct_id>NCT01720069</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma</brief_title>
  <official_title>A Randomised Double-blind, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of VR506 From a New Dry Powder Inhaler in Subjects With Severe Persistent Asthma Requiring Oral Corticosteroid Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vectura Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vectura Limited</source>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy, safety, tolerability and dose-response relationship, using
      oral corticosteroid (OCS) modulation, of 3 different doses of VR506 using a twice daily
      regimen from a new dry powder inhaler (nDPI) for 16 weeks in subjects with severe persistent
      asthma requiring OCS therapy, i.e. Step 5 treatment as defined by modified Global Initiative
      for Asthma (GINA) guidelines 2011.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Prednisone/Prednisolone Dose for Analysis (PDA)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The Asthma Control Prednisone/Prednisolone Dose at end of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In clinic measurements of FEV1, asthma control (ACQ) and Quality of Life and use of asthma control questionnaires</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of VR506 in subjects with asthma</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measure of vital signs, AEs, SAEs and number of withdrawals for worsening asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the subject's operation and handling of the nDPI</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessment of the Compliance with the treatment regimen; operation and acceptability of the device by use of questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dose 1 VR506</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VR506 inhalation powder delivered via a new dry powder inhaler device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 VR506</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VR506 inhalation powder delivered via a new dry powder inhaler device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 VR506</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VR506 inhalation powder delivered via a new dry powder inhaler device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VR506</intervention_name>
    <description>VR506 inhalation powder delivered via a new dry powder inhaler device</description>
    <arm_group_label>Dose 1 VR506</arm_group_label>
    <arm_group_label>Dose 2 VR506</arm_group_label>
    <arm_group_label>Dose 3 VR506</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Written informed consent

          -  Adolescents aged 12-17 years &amp; adults aged 18-65 years (both inclusive)

          -  Documented clinical history of severe asthma requiring prednisone/prednisolone
             therapy, high-intensity treatment ICS, OCS, LABA

          -  Stable OCS dose for ≥7 days before Screening Visit &amp; during Screening Period.

          -  At least 80% compliant w/regular asthma medication per investigator at end of
             Screening Period

          -  Documented asthma reversibility within 5 yrs prior to/during Screening Period, or
             diagnosis of asthma that is incontrovertible per investigator

          -  Ability to use nDPI correctly, per investigator's review of completed inhaler
             operation checklist

          -  Ability to use eDiary correctly, assessed by investigator at end of Screening Period

          -  Ability to comply w/study procedures, including blood sampling

          -  Ability to perform technically satisfactory pulmonary function tests

          -  Available to complete all study visits before 12 noon

          -  BMI of 16-26 kg/m2 in adolescents and 18-32 kg/m2 in adults

          -  Oral PIF ≥40 L/min, using an appropriate device set to match resistance of inhaler

          -  Good health, except for presence of asthma, per medical history/physical examination

          -  Negative drug/alcohol/urine cotinine screen. Subjects must test negative for
             amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine, ethanol
             &amp; opiates (unless given as prescription medicine)

          -  Non-smokers or ex-smokers with a smoking history of less than 10 pack-yrs (e.g. &lt;20
             cigarettes per day for 10 years or &lt;40 cigarettes per day for 5 years) &amp; stopped
             smoking for at least 1 year prior to Screening Visit. Smoking will not be permitted
             throughout study

          -  Female subjects of child-bearing potential must be using medically acceptable forms of
             contraception [abstinence, hormonal (oral/implant/transdermal/injection), in use for
             ≥3 consecutive months before first dose of study medication, double barrier (condom
             w/spermicide, or diaphragm w/spermicide), IUD, or vasectomised partner (≥6 months
             since vasectomy)].

        Exclusion:

          -  Regular use (≥3 times/wk) of topical steroids to treat dermatitis/rhinitis/allergic
             conjunctivitis, within 28 days of Screening Visit

          -  Subjects who have/who have had, an upper/lower respiratory tract infection within 28
             days of Screening Visit

          -  Subjects w/&quot;brittle asthma

          -  Subjects w/asthma that required admission to an ICU and/or ventilation within previous
             12 months

          -  Subjects whose comorbidities, per investigator's opinion, are major contributors to
             their respiratory symptoms (e.g. COPD, bronchiectasis, dysfunctional breathlessness,
             vocal cord dysfunction, gastro-oesophageal reflux)

          -  Previously/currently diagnosed as having Churg-Strauss syndrome

          -  Previously/currently diagnosed as having pulmonary eosinophilia

          -  History of lung cancer

          -  Subjects w/current diagnosis of HIV infection

          -  Active chronic hepatitis B or C infection

          -  Subjects who have clinically significant abnormality/finding from examination, tests,
             or history that may compromise subject safety, specifically any history of cardiac,
             renal or hepatic impairment

          -  Subjects with an abnormal ECG

          -  Persistent arterial hypotension, with average SBP readings of ≤95 mmHg

          -  Persistent elevation of blood pressure, with average SBP readings of ≥160 mmHg or
             average DBP readings of ≥100 mmHg

          -  Pregnant or lactating females

          -  Participation in another clinical study in 28 days prior to Screening Visit

          -  Evidence of clinically significant renal, hepatic, cardiac, pulmonary (apart from
             asthma) or metabolic dysfunction, e.g. diabetes mellitus, thyrotoxicosis,
             uncorrectable hypokalaemia, or predisposition to low levels of serum potassium

          -  Current/history of drug/alcohol abuse/dependence per WHO criteria

          -  Inability to communicate well w/investigator

          -  Donation of ≥450 mL of blood/blood products within previous 3 months prior to
             screening

          -  History of allergy/intolerance/contraindications to corticosteroids/lactose, or severe
             allergy to milk proteins

          -  Consumption of alcohol- or caffeine-containing foods/beverages from midnight before or
             during Screening Visit

          -  History of medically diagnosed chronic respiratory diseases other than asthma (e.g.
             chronic obstructive pulmonary disease, ABPA in the absence of asthma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01001</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinial Trial Site 01005</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01006</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01015</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01012</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01014</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01003</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01011</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01013</name>
      <address>
        <city>Jersey City</city>
        <state>New Jersey</state>
        <zip>07306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01004</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 01007</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 08006</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 08005</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 08001</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 08003</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 08007</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 08004</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 08002</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 08008</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 03006</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 03009</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 03004</name>
      <address>
        <city>Bonn</city>
        <zip>53119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 03008</name>
      <address>
        <city>Donaustauf</city>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 03003</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 03007</name>
      <address>
        <city>Geesthacht</city>
        <zip>21502</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 03001</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 03005</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 03002</name>
      <address>
        <city>Rudersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 04001</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 04004</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 04003</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 04002</name>
      <address>
        <city>Rakoczi</city>
        <zip>125 127</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 04005</name>
      <address>
        <city>Rakoczi</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05008</name>
      <address>
        <city>Bialystok</city>
        <zip>15-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05002</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05010</name>
      <address>
        <city>Bialystok</city>
        <zip>15-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05011</name>
      <address>
        <city>Krakow</city>
        <zip>31-024</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05001</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05006</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05005</name>
      <address>
        <city>Lublin</city>
        <zip>20-552</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05007</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05003</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05009</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 05004</name>
      <address>
        <city>Zawadzkie</city>
        <zip>47-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07001</name>
      <address>
        <city>Brasov</city>
        <zip>500086</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07008</name>
      <address>
        <city>Bucuresti</city>
        <zip>010457</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07005</name>
      <address>
        <city>Bucuresti</city>
        <zip>020671</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07013</name>
      <address>
        <city>Bucuresti</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07003</name>
      <address>
        <city>Bucuresti</city>
        <zip>050554</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07006</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07007</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07009</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07010</name>
      <address>
        <city>Cod</city>
        <zip>700115</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07014</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07002</name>
      <address>
        <city>Iasi</city>
        <zip>700376</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07004</name>
      <address>
        <city>Marghita</city>
        <zip>415300</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 07012</name>
      <address>
        <city>Targu Mures</city>
        <zip>540543</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinicl Trial Site 07011</name>
      <address>
        <city>Timis</city>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06013</name>
      <address>
        <city>AR Crimea</city>
        <zip>97403</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06009</name>
      <address>
        <city>Donetsk</city>
        <zip>83099</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06012</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06010</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06001</name>
      <address>
        <city>Kharkiv</city>
        <zip>61035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06004</name>
      <address>
        <city>Kharkiv</city>
        <zip>61106</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06006</name>
      <address>
        <city>Kyiv</city>
        <zip>02232</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06002</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06015</name>
      <address>
        <city>Kyiv</city>
        <zip>3680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06003</name>
      <address>
        <city>Kyviv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06008</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06011</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06007</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 06014</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 02003</name>
      <address>
        <city>Cottingham</city>
        <state>Hull</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial site 02002</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 02004</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 02001</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 02005</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2012</study_first_submitted>
  <study_first_submitted_qc>October 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <disposition_first_submitted>September 11, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>September 11, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 22, 2014</disposition_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

